Clinical studies of CTB‐ACE2/Ang1‐7 are now underway to determine the safety, tolerability and pharmacodynamics of oral ACE2/Ang1‐7 in healthy volunteers (phase 1a) and patients with COVID‐19 (phase 1b). Here, ACE2 is linked to COVID-19.